Novel targeted therapies for the treatment of metastatic melanoma

Ochsner Journal

Volumn 10, Issue 2, 2010, Pages 117-124

  Kudchadkar, Ragini ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

BRAF; MAP kinase; Melanoma; PI 3 kinase; Sorafenib

Indexed keywords

4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; 5 AZA 2' DEOXYCYTIDINE; 7 HYDROXYSTAUROSPORINE; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; BEVACIZUMAB; BORTEZOMIB; CHIR 265; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DEFOROLIMUS; ELESCLOMOL; EVEROLIMUS; FLAVOPIRIDOL; IMATINIB; INTERLEUKIN 2; LONAFARNIB; MITOGEN ACTIVATED PROTEIN KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; OBLIMERSEN; PHOSPHATIDYLINOSITOL 3 KINASE; PI 88; PLX 4032; PROTEIN P53; RETINOBLASTOMA PROTEIN; SORAFENIB; TANESPIMYCIN; TEMSIROLIMUS; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 147; XL 281;

ARTICLE; CELL CYCLE; CLINICAL TRIAL; DRUG MEGADOSE; DRUG TARGETING; HUMAN; MELANOMA; METASTASIS; NONHUMAN; SIGNAL TRANSDUCTION;

EID: 77954873269     PISSN: 15245012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Carbone PP, Costell W. Eastern Cooperative Oncology Group studies with DTIC (NSC-45388). Cancer Treat Rep. 1976;60:193-198.
2. Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group [published online ahead of print September 11, 2006]. J Clin Oncol. 2006;24:4738-4745.
3. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105-2116.
4. Slominski A, Tobin DJ, Shibahara S, Wortsman J. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev. 2004;84:1155-1228.
5. Haass NK, Smalley KS, Herlyn M. The role of altered cell-cell communication in melanoma progression. J Mol Histol. 2004;35:309-318.
6. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alternation in melanoma. N Engl J Med. 2005;353:2135-2147.
7. Sekulic A, Haluska P Jr, Miller AJ, et al. Malignant elanoma in the 21st century: the emerging molecular landscape. Mayo Clin Proc. 2008;83:825-846.
8. Meyer LJ, Zone JH. Genetics of cutaneous melanoma. J Invest Dermatol. 1994;103(5 suppl):112-116.
9. Meyer LJ, Piepkorn M, Goldgar DE, et al. Penetrance and expressivity of the chromosome 9p melanoma susceptibility locus (MLM). Cancer Res. 1994;54:6041-6044.
10. Rulyak SJ, Brentnall TA, Lynch HT, Austin MA. Characterization of the neoplastic phenotype in the familial atypical multiple-mole melanoma-pancreatic carcinoma syndrome. Cancer. 2003; 98:798-804.
11. Goldstein AM, Chan M, Harland M, et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents [published online ahead of print August 11, 2007]. J Med Genet. 2007;44:99-106.
12. Bennett DC. How to make a melanoma: what do we know of the primary clonal events? Pigment Cell Melanoma Res. 2008;21:27-38.
13. Marini A, Mirmohammadsadegh A, Nambiar S, Gustrau A, Ruzicka T, Hengge UR. Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma. J Invest Dermatol. 2006;136:422-431.
14. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28:622-629.
15. Gollob JA, Sciambi CJ, Peterson BL, et al. Phase I trial of sequential low-dose 5-aza-29-deosycytidien plus high-dose intravenous bolus interlekin-2 in patients with melanoma or renal cell carcinoma. Clin Cancer Res. 2006;12:4619-4627.
16. Burdette-Radoux S, Tozer RG, Lohmann RC, et al. Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Invest New Drugs. 2004; 22:315-322.
17. Fecher L, Amaravadi RK, Flaherty KT. The MAPK pathway in melanoma. Curr Opin Oncol. 2008;20:183-189.
18. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer [published online ahead of print June 9, 2002]. Nature. 2002;417:949-954.
19. Ball NJ, Yohn JJ, Morelli JG, Norris DA, Golitz LE, Hoeffler JP. Ras mutation in human melanoma: a marker of malignant progression. J Invest Dermatol. 1994;102:285-290.
20. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature. 2007;445:851-857.
21. Panka DJ, Wang W, Atkins MB, Mier JW. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res. 2006;66:1611-1619.
22. Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a phase II randomized discontinuation trial analysis [published online ahead of print August 1, 2006]. Br J Cancer. 2006;95:581-586.
23. Flaherty KT, Schiller J, Schuchter LM, et al. A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res. 2008;14:4836-4842.
24. Hauschild A, Agarwala SS, Trefzer U, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma [published online ahead of print April 6, 2009]. J Clin Oncol. 2009;27:2823-2830.
25. Pharmaprojects. Nexavar fails Phase III melanoma trial. Available at: http://www.pharmaprojects.com/news/3004_1605.htm. Accessed May 10, 2010.
26. McDermott DF, Sosman JA, Gonzalez R, et al. A double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol. 2008;26:2178-2185.
27. Amiri P, Aikawa ME, Dove J. CHIR-265 is a potent selective inhibitor of c-Raf/B-RAF/mutB-Raf that effectively inhibits proliferation and survival of cancer cell lines with Ras/Raf pathway mutations. In: Proceedings from the American Association for Cancer Research; 2006;47: Abstract 4855.
28. Flaherty K, Puzanov I, Sosman J, et al. Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol. 2009;27(15 suppl): Abstract 9000.
29. LoRusso PM, Krishnamurthi SS, Rinehart JJ, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ ERK kinase inhibitor PD-0325901 in patients with advanced cancers [published online ahead of print March 9, 2010]. Clin Cancer Res. 2010;16:1924-1937.
30. Dummer R, Robert C, Chapman PB, et al. AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients wth advanced melanoma: an open-label randomized, multicenter, phase II study. J Clin Oncol. 2008;26: Abstract 9033.
31. Stahl JM, Cheung M, Sharma A, Trivedi NR, Shanmugam S, Robertson GP. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res. 2003;63:2881-2890.
32. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 2000;14:2501-2514.
33. Bugering BM, Medema RH. Decisions of life and death: FOXO Forkhead transcription factors are in command when PKB/AKT is off duty. J Leukoc Biol. 2003;73:689-701.
34. Lou JJ, Manning BD, Cantley LC. Targeting the PI3K-AKT pathway in human cancer: rationale and promise. Cancer Cell. 2003; 4:257-262.
35. Satyamoorthy K, Li G, Vaidya B, Patel D, Herlyn M. Insulin-like growth factor-1 induces survival and growth of biologically early melanoma cells through both the mitogen-activated protein kinase and beta-catenin pathways. Cancer Res. 2001;61:7318-7324.
36. Smalley K, Herlyn M. Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics. Ann NY Acad Sci. 2005;1059:16-25.
37. Tsao H, Zhang X, Fowlkes K, Haluska FG. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res. 2000;60:1800-1804.
38. Stahl JM, Sharma A, Cheung M, et al. Deregulated AKT3 activity promotes development of malignant melanoma. Cancer Res. 2004;64:7002-7010.
39. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther. 2003;2:1093-1103.
40. Ernst DS, Eisenhauer E, Wainman N, et al. Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest New Drugs. 2005;23:569-575.
41. Margolin K, Longmate J, Baratta T, et al. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer. 2005;104:1045-1048.
42. Rao RD, Windschitl HE, Allred JB, et al. Phase II trial of the mTOR inhibitor everolimus (RAD-001) in metastatic melanoma. J Clin Oncol. 2006;24(18s): Abstract 8043.
43. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24(26): 4340-4347.
44. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000;295:139-145.
45. Kim KB, Eton O, Davis DW, et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma [published online ahead of print August 19, 2008]. Br J Cancer. 2008;99:734-740.
46. McNulty SE, Tohidian NB, Meyskens FL. RelA, p50 and inhibitor of kappa B alpha are elevated in human metastatic melanoma cells and respond aberrantly to ultraviolet light B. Pigment Cell Res. 2001;14:456-465.
47. Kuphal S, Poser I, Jobin C, Hellerbrand C, Bosserhoff AK. Loss of e-cadherin leads to upregulation of NFkappaB activity in malignant melanoma. Oncogene. 2004;23:8509-8519.
48. Amiri KI, Horton LW, LaFleur BJ, Sosman JA, Richmond A. Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib as a therapeutic agent for malignant melanoma. Cancer Res. 2004;64:4912-4918.
49. Markovic SN, Geyer SM, Dawkins F, et al. A phase II study of bortezomib in the treatment of metastatic melanoma. Cancer. 2005;103:2584-2589.
50. Sosman JA, Puzanov I. Molecular targets in melanoma from angiogenesis to apoptosis. Clin Cancer Res. 2006;12: 2376s-2383s.
51. Bush JA, Li G. The role of Bcl-2 family members in the progression of cutaneous melanoma. Clin Exp Metastasis. 2003;20:531-539.
52. Nishimura EK, Granter SR, Risher ED. Mechanism of hair graying: incomplete melanocyte stem cell maintenance in the niche [published online ahead of print December 23, 2004]. Science. 2005;307:720-724.
53. Schmitt CA, Rosenthal CT, Lowe SW. Genetic analysis of chemoresistence in primary murine lymphomas. Nat Med. 2000;6:1029-1035.
54. Jansen B, Schlagbauer-Wadl H, Brown BD, et al. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med. 1998;2:232-234.
55. Genta Incorporated. Genta announces top-line results of AGENDA phase 3 trial of GenasenseH in patients with advanced melanoma. Available at: http://www.genta.com/Press_Releases/2009/Genta_Announces_Top-Line_Results_of_AGENDA_Phase_3_Trial_of_GenasenseH_in_Patients_with_Advanced_Melanoma.html. Accessed May 10, 2010.
56. Welch WJ, Feramisco JR. Purification of the major mammalian heat shock proteins. J Biol Chem. 1982;257:14949-14959.
57. McCarthy MM, Pick E, Kluger Y, et al. HSP90 as a marker of progression in melanoma [published online ahead of print November 23, 2007]. Ann Oncol. 2008;19:590-594.
58. Banerji U, O'Donnell A, Scurr M, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol. 2005;23:4152-4161.
59. O'Day S, Gonzalez R, Lawson D, et al. Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma [published online ahead of print October 13, 2009]. J Clin Oncol. 2009;27:5452-5458.
60. Hauschild A, Eggermont AM, Jacobson E, O'Day SJ. Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM). J Clin Oncol. 2009;27(18s): Abstract 9012.